

Select Publications from Dr. David Lacomis:

- ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. *Neurology* 1996;46:1244-1249.
- Lacomis D**, Giuliani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. *Ann Neurol* 1996;40:645-654.
- Campellone JV, **Lacomis D**, Kramer DJ, Van Cott AC, Giuliani MJ. Acute myopathy after liver transplantation. *Neurology* 1998;50:46-53.
- Stambler N, Charatan M, Cedarbaum JM, and the ALS CNTF Treatment Study Group. Prognostic indicators of survival in ALS. *Neurology* 1998;50:66-72.
- Hebert RS, **Lacomis D**, Easter C, Frick V, Shear MK. Grief support for informal caregivers of ALS patients: a national survey. *Neurology*, 2005;64:137-138.
- Lacomis D**. Myasthenic crisis. *Neurocritical Care* 2005;03:189-194.
- Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, **Lacomis D**, Urbinelli L, Newhall K, Cudkowicz ME, Brown Jr RH, Bowser R. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. *J Neurochem* 2005;95:1461-1471.
- Cudkowicz ME, Shefner JM, Schoenfeld DA, Hui Z, Andreasson KI, Rothstein JD, Drachman DB, and the Northeast ALS Consortium. Trial of celecoxib in amyotrophic lateral sclerosis. *Ann Neurol* 2006;60:22-31.
- Ranganathan S, Georgina CBN, Henry S, Lutka F, Sathanoori R, **Lacomis D**, Bowser R. Comparative proteomic profiling of cerebrospinal fluid between living and postmortem ALS and control subjects. *Amyotrophic Lateral Sclerosis*, 2007;8:373-379.
- Wang H, Larrieviere KS, Keller KE, Ware KA, Burns TM, Conaway MA, **Lacomis D**, Pattee GL, Phillips LH, Solenski NJ, Zivkovic SA, Bennett JP. R(+) pramipexole as a mitochondrially focused neuroprotectant: Initial phase II studies in ALS. *Amyotrophic Lateral Sclerosis* 2007;9:50-58.